{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:24:48Z","timestamp":1777929888007,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Palliative Medicine Reports"],"published-print":{"date-parts":[[2022,8]]},"abstract":"\n Background:<\/jats:title>\n The effectiveness of tolvaptan (T) for treating pedal edema remains unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n We aimed to clarify the effectiveness of diuretics, including T, on pedal edema in advanced cancer patients, and to compare patients' versus physicians' assessments of the effects.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Participants comprised 88 hospitalized cancer patients treated with T, loop diuretics (L), or spironolactone (S). Patient characteristics, initial doses of diuretics, reason for discontinuation, side effects, evaluation of pedal edema, and effects of diuretics on pedal edema were investigated retrospectively using electronic medical records.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The rates of improvement of pedal edema according to patients (Pt) and physicians (MD) were T: Pt 83.3% (\n n<\/jats:italic>\n \u2009=\u20096), MD 71.4% (\n n<\/jats:italic>\n \u2009=\u200914); L: Pt 57.1% (\n n<\/jats:italic>\n \u2009=\u200914), MD 50.0% (\n n<\/jats:italic>\n \u2009=\u200926); S: Pt 0% (\n n<\/jats:italic>\n \u2009=\u20091), MD 57.1% (\n n<\/jats:italic>\n \u2009=\u20097); L+S: Pt 83.3% (\n n<\/jats:italic>\n \u2009=\u200912), MD 69.0% (\n n<\/jats:italic>\n \u2009=\u200929); T+L: Pt 90.9% (\n n<\/jats:italic>\n \u2009=\u200922), MD 71.8% (\n n<\/jats:italic>\n \u2009=\u200939); T+S: Pt 0% (\n n<\/jats:italic>\n \u2009=\u20091), MD 0% (\n n<\/jats:italic>\n \u2009=\u20092); T+L+S: Pt 62.5% (\n n<\/jats:italic>\n \u2009=\u20098), MD 69.2% (\n n<\/jats:italic>\n \u2009=\u200913). In 57.1%\u201390.9% and 50.0%\u201371.8% of episodes, patients and physicians, respectively, observed some effectiveness of diuretics on pedal edema in advanced cancer, except for in the S (Pt) and T\u2009+\u2009S (Pt, MD) groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n The treatment of pedal edema improves patient symptoms, enhancing quality of life. Further verification and evaluation of the effect of T on pedal edema are needed.<\/jats:p>\n <\/jats:sec>","DOI":"10.1089\/pmr.2022.0017","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T14:50:36Z","timestamp":1660920636000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the Effects of Diuretics on Pedal Edema in Patients with Cancer"],"prefix":"10.1177","volume":"3","author":[{"given":"Sari","family":"Nakagawa","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan."},{"name":"Department of Pharmacy, Ashiya Municipal Hospital, Ashiya, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouhei","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouhei","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuko","family":"Tsunoda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ashiya Municipal Hospital, Ashiya, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ashiya Municipal Hospital, Ashiya, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"issue":"1","key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.5535\/arm.2018.42.1.166","volume":"42","author":"Lee CH","year":"2018","unstructured":"Lee CH, , Kim JK, , Jun HJ, et al. Rehabilitation of advanced cancer patients in palliative care unit. Ann Rehabil Med, 2018; 42(1):166\u2013174; doi: 10.5535\/arm.2018.42.1.166.","journal-title":"Ann Rehabil Med"},{"key":"e_1_3_2_3_2","unstructured":"International Lymphoedema Framework. The Management of Lymphoedema in Advanced Cancer and Oedema at the End of Life. Medical Education Partnership: London UK; 2010. https:\/\/www.lympho.org\/wp-content\/uploads\/2021\/09\/Focus-Frameworks.pdf."},{"issue":"3","key":"e_1_3_2_4_2","first-page":"991","volume":"27","author":"Penn IW","year":"2018","unstructured":"Penn IW, , Chang YC, , Chuang E, et al. Risk factors and prediction model for persistent breast-cancer-related lymphedema: A 5-year cohort study. Support Care Cancer, 2018; 27(3):991\u20131000; doi: 10.1007\/s00520-018-4388-6.","journal-title":"Support Care Cancer"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/CLEP.S47150","volume":"5","author":"S\u00f8gaard M","year":"2013","unstructured":"S\u00f8gaard M, , Thomsen RW, , Bossen KS, et al. The impact of comorbidity on cancer survival: A review. Clin Epidemiol, 2013; 5(Suppl. 1):3\u201329; doi: 10.2147\/CLEP.S47150.","journal-title":"Clin Epidemiol"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcws.2010.04.004"},{"key":"e_1_3_2_7_2","unstructured":"Keeley V. Oedema in advanced cancer. In: Twycross R Jenns K Todd J (eds): Lymphoedema. Oxford: Radcliffe Medical Press 2000 338\u2013358."},{"issue":"3","key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","volume":"287","author":"Yamamura Y","year":"1998","unstructured":"Yamamura Y, , Nakamura S, , Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther, 1998; 287(3):860\u2013867.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2007.00001.x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656561003610656"},{"issue":"1","key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10557-011-6304-x","volume":"25","author":"Matsuzaki M","year":"2011","unstructured":"Matsuzaki M, , Hori M, , Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther, 2011; 25(1):33\u201345; doi: 10.1007\/s10557-011-6304-x.","journal-title":"Cardiovasc Drugs Ther"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12098"},{"key":"e_1_3_2_13_2","volume":"18","author":"Wang S","year":"2018","unstructured":"Wang S, , Zhang X, , Han T, et al. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. BMC Gastroenterol, 2018; 18(1):137; doi: 10.1186\/s12876-018-0857-0.","journal-title":"BMC Gastroenterol"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2017.12.481"},{"issue":"7","key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00535-021-01788-x","volume":"56","author":"Yoshiji H","year":"2021","unstructured":"Yoshiji H, , Nagoshi S, , Akahane T, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol, 2021; 56(7):593\u2013619; doi: 10.1007\/s00535-021-01788-x.","journal-title":"J Gastroenterol"}],"container-title":["Palliative Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/pmr.2022.0017","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/pmr.2022.0017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/pmr.2022.0017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:56:43Z","timestamp":1777679803000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/pmr.2022.0017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1089\/pmr.2022.0017"],"URL":"https:\/\/doi.org\/10.1089\/pmr.2022.0017","relation":{},"ISSN":["2689-2820","2689-2820"],"issn-type":[{"value":"2689-2820","type":"print"},{"value":"2689-2820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]},"article-number":"pmr.2022.0017"}}